For Healthcare Professionals

Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations

clipboard-pencil

About the study

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

    EXCLUSION CRITERIA

      pin location

      Study Locations

      Enter your ZIP code/Postal code/PIN code to locate study sites near you:

      How to Apply


      Contact the study center to learn if this study is a good match for you.
      Phone iconCall 1-877-240-9479Email iconEmail Study Center

      Study’s details


      Contition

      NSCLC

      Age (in years)

      18 - 130

      Phase

      Phase 3

      Participants needed

      1000

      Est. Completion Date

      May 2027

      Treatment type

      Interventional


      Sponsor

      AstraZeneca

      ClinicalTrials.gov identifier

      NCT05687266

      Study number

      D926NC00001

      Understanding Clinical Trials


      Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
      Vector

      Interested?

      Sign up to save your favorites, 
      receive newsletters, resources, and alerts 
      about clinical trials related to your conditions of interest.